Latham & Watkins Advises ITM on Obtaining Exclusive Worldwide License From Debiopharm for Cancer Treatment

Latham & Watkins LLP has advised ITM Isotope Technologies Munich SE on an agreement with Debiopharm for obtaining an exclusive global license for the clinical and commercial development of the peptide-based, theranostic pair ITM-91/ITM-94D. Debiopharm is to receive development and regulatory milestone payments of approximately €300 million, as well as commercial milestones and low double-digit royalties on future sales.

ITM is a leading radiopharmaceutical biotech company, dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors.

Debiopharm is a Switzerland-based, global biopharmaceutical company. As drug development expert, the company has an evolving radioligand therapy pipeline and strong pre-clinical and clinical competence in this field.

The theranostic pair ITM-91/ITM-94D is targeting a surface protein, which plays a key role in the tumor microenvironment, promoting tumor growth, survival, invasion, and metastasis. It is currently being evaluated in a clinical trial in patients living with locally advanced kidney cancer, pancreatic cancer, or colorectal cancer.

The Latham team was led by Frankfurt corporate/IP partner Susan Kempe-Müller with associates Johannes Huschka and Daniela Jaeger. Advice was also provided on commercial matters by Frankfurt partner Christina Mann; on healthcare regulatory matters by Hamburg partner Christoph Engeler with associate Henrietta Ditzen; and on data privacy matters by Frankfurt counsel Wolf-Tassilo Böhm.